Methods
An Analysis of the Pediatric Sub-group from the Phase 2 Study of GMI-1070

TL McCavil, L. Krishnamurti, L Hsu, CT Quinn*, I Odame, O Alvarez, C Driscoll, K Smith Whitley, T Rhein, W. Tulin, M. Telen, H. Thackray

1 UT Southwestern Medical Center, Dallas, TX; 2 University of Pittsburgh Medical Center, Pittsburgh, PA; 3 Columbia University Medical Center, Chicago, IL; 4 Cincinnati Children’s Hospital Medical Center, Cincinnati, OH; 5 Hospital for Sick Children, Toronto, ON, Canada; 6 University of Miami Miller, Miami, FL; 7 Albert Einstein College of Medicine, New York, NY; 8 Children’s Hospital of Philadelphia, Philadelphia, PA; 9 Rhino Inc., Chapel Hill, NC; 10 University of California, Davis Medical Center and VANCHS, Sacramento, CA; 11 Duke University Medical Center, Durham, NC; 12 GlycoMimetics Inc., Gaithersburg, MD

Background

- Pain is a prevalent clinical issue that requires adequate management.
- The use of opioids is common in pediatric patients for pain management.
- The safety and efficacy of new treatments are crucial for improving pain management in children.

Inclusion Criteria:
- Age 2 to 17 years
- Diagnosed with VON
- No prior treatment with GMI 1070

Exclusion Criteria:
- Known hypersensitivity to GMI 1070 or placebo
- Presence of an active infection
- Presence of a malignancy
- Known drug or alcohol addiction

Methods

- Study design: Randomized, double-blind, placebo-controlled phase 2 clinical trial
- Two treatment arms: GMI 1070 and placebo
- Study duration: 48 hours
- Primary outcome: Time to readiness for discharge

Results

- GMI 1070 demonstrated a significant decrease in pain scores compared to placebo.
- Adverse events were comparable between the two groups.

Safety
- No serious adverse events were reported.
- No treatment-related deaths occurred.

Conclusions

- GMI 1070 shows promise in improving pain management in pediatric patients with VON.
- Further studies are needed to confirm these findings.

For more information and related GlycoMimetics projects, visit glycomimetics.com

An Analysis of the Pediatric Sub-group from the Phase 2 Study of GMI-1070

TL McCavil, L. Krishnamurti, L Hsu, CT Quinn*, I Odame, O Alvarez, C Driscoll, K Smith Whitley, T Rhein, W. Tulin, M. Telen, H. Thackray

1 UT Southwestern Medical Center, Dallas, TX; 2 University of Pittsburgh Medical Center, Pittsburgh, PA; 3 Columbia University Medical Center, Chicago, IL; 4 Cincinnati Children’s Hospital Medical Center, Cincinnati, OH; 5 Hospital for Sick Children, Toronto, ON, Canada; 6 University of Miami Miller, Miami, FL; 7 Albert Einstein College of Medicine, New York, NY; 8 Children’s Hospital of Philadelphia, Philadelphia, PA; 9 Rhino Inc., Chapel Hill, NC; 10 University of California, Davis Medical Center and VANCHS, Sacramento, CA; 11 Duke University Medical Center, Durham, NC; 12 GlycoMimetics Inc., Gaithersburg, MD